Navigation Links
Mercury Therapeutics Patents Filed
Date:3/31/2008

rapid progress MTI has made in the design and synthesis of novel AMPK activators, I am optimistic that we will be filing an IND by the end of 2009 to initiate clinical trials focusing on Type-2 diabetics who no longer respond to metformin or other available oral therapies."

About Mercury Therapeutics, Inc. (http://www.mtipharm.com)

MTI is an early stage drug discovery company focusing on the development of small molecule candidates against a number of selected protein kinase drug targets in metabolic diseases and oncology. MTI's main focus is on the discovery and development of orally active small molecule activators of AMPK, a well-validated though largely unexploited, protein kinase drug target in metabolic disease. While a number of anti-diabetic drugs currently on the market, including metformin (Glucophage(R)) and pioglitazone (Actos(R)), act indirectly to activate AMPK, MTI is seeking to develop the first orally available direct AMPK activator. The potential indications of a successful AMPK targeted drug include Type-2 diabetes, hyperlipidemia, obesity, metabolic syndrome and endocrine cancers.

MTI was launched in 2001, and has an exclusive license to a patent from Dartmouth College and St. Vincent's Institute for Biomedical Research in Melbourne, Australia for AMP activated protein kinase (AMPK). In June 2001, MTI launched its R&D operations following execution of a collaboration agreement with Aventis, AG to develop AMPK activators to treat Type-2 diabetes and obesity. In June 2004, Aventis was acquired by Sanofi, and MTI re-acquired all of its intellectual property rights to AMP kinase as well as the rights to develop compounds identified during the collaboration. In October, 2004: MTI secured external financing from XL TechGroup, Inc. In Q4 2005, MTI demonstrated its first preclinical proof-of-principle of active compounds in a glucose tolerance test in mice.

For furthe
'/>"/>

SOURCE Mercury Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
2. Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... difficult to manufacture proteins including biosimilar therapeutics, today ... for the second quarter ended June 30, 2014. ... initial public offering, we have the capital to ... from our proprietary protein expression platform," stated Bertrand ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... reported financial results for the six months ended ... expressed in Canadian dollars and presented under International ... 2014 Highlights , Announced top-line results ... primary endpoint for subjects enrolled in the Phase ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Intrinsic ... 13485:2003 certified, GAMP® 5 compliant imaging core lab, ... international Phase II clinical trial to assess a ... Throughout this trial, Intrinsic Imaging will provide comprehensive ... to, protocol and charter development, site qualification, site ...
(Date:8/28/2014)... Ind. A new research platform uses ... of tiny structures undergoing stress and heating, ... improve designs for microelectronics and batteries., This ... information about how heating and the surface ... properties. Researchers have discussed the merits of ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3
... N.Y. Researchers at Rensselaer Polytechnic Institute have ... of gold that measure only billionths of a ... equipment and works on nearly any surface including ... and semiconductor manufacturing. Sang-Kee Eah, assistant professor ...
... June 16 Trans World Alloys (TWA), one of the country,s ... Brennan has joined the company, as its new Chief Operating Officer. ACCORDING ... years experience in the metal business in a variety of areas." , ... Ed has attended the University of ...
... , , ... Thorne Ltd. (TSX-V: HTL), a leading provider of advanced laser systems and ... the launch of the Staccato(TM) multi-pulse laser system at the 8th Annual ... 16-19, 2010 , in San Francisco, CA. Staccato(TM) will add ...
Cached Biology Technology:Researchers develop ultra-simple method for creating nanoscale gold coatings 2Ed Brennan - New C.O.O. of Trans World Alloys 2Hamilton Thorne to launch Staccato(TM) laser at International Society of Stem Cell Research Annual Meeting 2Hamilton Thorne to launch Staccato(TM) laser at International Society of Stem Cell Research Annual Meeting 3Hamilton Thorne to launch Staccato(TM) laser at International Society of Stem Cell Research Annual Meeting 4
(Date:8/28/2014)... healthier for your neighbors than traditional cigarettes, but ... a new study from USC. , Scientists studying ... decrease in exposure to harmful particles, with close-to-zero ... to some harmful metals in second-hand e-cigarette smoke ... tobacco smoke contains high levels of polycyclic aromatic ...
(Date:8/28/2014)... MINNEAPOLIS/ST. PAUL (August 28, 2014) Researchers at the ... for facioscapulohumeral muscular dystrophy (FSHD) to be used for ... effectiveness of potential therapies for FSHD. , The research ... Cell Reports . , There is no treatment ... the most common type of muscular dystrophy. FSHD is ...
(Date:8/28/2014)... N.C. -- Scientists have identified the developmental on-off switch ... that produce more than two-thirds of the world,s naturally ... be to see whether it is possible to manipulate ... , The study, appearing August 28 in ... small molecule called cyclic-di-GMP and a larger protein called ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2UMN researchers find animal model for understudied type of muscular dystrophy 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... MINNETONKA, Minn., Feb. 8, 2011 MedNet Solutions, ... in clinical study management systems, is pleased to ... the company,s flagship eClinical solution.  The ENLIGHTEN ... and easy-to-use electronic data capture (EDC) and clinical ...
... of the turtle world swimming farther, diving deeper and ... But for all their toughness, they have still suffered a ... Ocean over the last 20-plus years, largely at the hands ... tagging and tracking the turtles are providing insights into their ...
... their ability to exhibit the "Cheerios effect" when they move ... together like Cheerios swimming in milk in a cereal bowl ... has made Virginia Tech engineers speculate about the possible impacts ... the journal, Soft Matter , a publication of the ...
Cached Biology News:MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution 2Why leatherback turtles linger in South Pacific Gyre, and why it matters 2Why leatherback turtles linger in South Pacific Gyre, and why it matters 3Why leatherback turtles linger in South Pacific Gyre, and why it matters 4When worms stick together and swim on thin water, what happens and why does it matter? 2
... choice of PDMS Stamps (3 PDMS micropatterned ... micron squares or 100 um x 10 ... lines, 3 PDMS nano-patterned stamps with depth ... pitch of 400 nm, or 3 PDMS ...
Request Info...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Request Info...
Biology Products: